Oscar Fernandez

Summary

Country: Spain

Publications

  1. pmc Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain
    Oscar Fernandez
    Hospital Universitario Carlos Haya de Málaga, Malaga, Spain
    PLoS ONE 7:e35600. 2012
  2. ncbi [Biomarkers in multiple sclerosis]
    Oscar Fernandez
    Hospital Universitario Carlos Haya, 29190 Malaga, Spain
    Rev Neurol 56:375-90. 2013
  3. pmc Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis
    Oscar Fernandez
    Department of Neurology, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    J Cent Nerv Syst Dis 4:117-33. 2012
  4. ncbi Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)
    O Fernandez
    Fundacion IMABIS, Hospital Universitario Carlos Haya, 29190 Malaga, Espana
    Rev Neurol 57:269-81. 2013
  5. doi Integrating the tools for an individualized prognosis in multiple sclerosis
    O Fernandez
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Avenida Carlos Haya s n, 29010, Malaga, Spain
    J Neurol Sci 331:10-3. 2013
  6. doi Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis
    Oscar Fernandez
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Spain
    Expert Rev Clin Pharmacol 5:649-65. 2012
  7. pmc Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study
    O Fernandez
    Institute of Clinical Neurosciences, Carlos Haya Regional University Hospital, Avenida Carlos Haya s n, 29010 Malaga, Spain
    J Neurol 259:1814-23. 2012
  8. ncbi Spanish consensus on the use of natalizumab (Tysabri(®))--2011
    O Fernandez
    Servicio de Neurologia, Instituto de Neurociencias clínicas, Hospital Regional Universitario Carlos Haya, IMABIS, Malaga, Spain
    Neurologia 27:432-41. 2012
  9. ncbi Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)
    Oscar Fernandez
    Fundacion IMABIS, Hospital Universitario Carlos Haya, Avda Carlos Haya s n, Malaga, Spain
    Rev Neurol 54:734-49. 2012
  10. ncbi Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)
    Oscar Fernandez
    Hospital Regional Universitario Carlos Haya, Malaga, Espana
    Rev Neurol 54:677-91. 2012

Collaborators

Detail Information

Publications40

  1. pmc Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain
    Oscar Fernandez
    Hospital Universitario Carlos Haya de Málaga, Malaga, Spain
    PLoS ONE 7:e35600. 2012
    ..For that reason, the main objectives of this study are to assess adherence to INFβ-1b in patients suffering from MS in Spain, and to identify the factors responsible for adherence in routine clinical practice...
  2. ncbi [Biomarkers in multiple sclerosis]
    Oscar Fernandez
    Hospital Universitario Carlos Haya, 29190 Malaga, Spain
    Rev Neurol 56:375-90. 2013
    ....
  3. pmc Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis
    Oscar Fernandez
    Department of Neurology, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    J Cent Nerv Syst Dis 4:117-33. 2012
    ..All these results, together with its proven long-term safety and positive effect on patients' daily living, support the favorable risk-benefit of GA for multiple sclerosis treatment...
  4. ncbi Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)
    O Fernandez
    Fundacion IMABIS, Hospital Universitario Carlos Haya, 29190 Malaga, Espana
    Rev Neurol 57:269-81. 2013
    ....
  5. doi Integrating the tools for an individualized prognosis in multiple sclerosis
    O Fernandez
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Avenida Carlos Haya s n, 29010, Malaga, Spain
    J Neurol Sci 331:10-3. 2013
    ..Several mathematical approaches to estimate the risk of short term use early clinical and paraclinical biomarkers to predict the evolution of the disease. ..
  6. doi Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis
    Oscar Fernandez
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Spain
    Expert Rev Clin Pharmacol 5:649-65. 2012
    ..Prolonged-release fampridine Timed-Walk Responders showed both clinically significant improvements in walking speed and in patient-reported walking ability...
  7. pmc Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study
    O Fernandez
    Institute of Clinical Neurosciences, Carlos Haya Regional University Hospital, Avenida Carlos Haya s n, 29010 Malaga, Spain
    J Neurol 259:1814-23. 2012
    ..The 86 participating centers throughout Spain submitted data on disease characteristics at baseline and after treatment. Valid data were available for 1,364 patients (69.3% women, 86.9% with relapsing–remitting disease)...
  8. ncbi Spanish consensus on the use of natalizumab (Tysabri(®))--2011
    O Fernandez
    Servicio de Neurologia, Instituto de Neurociencias clínicas, Hospital Regional Universitario Carlos Haya, IMABIS, Malaga, Spain
    Neurologia 27:432-41. 2012
    ..The aim of this article is to provide a consensus view on the assessment and stratification of these risks, and to improve the management of natalizumab-treated patients...
  9. ncbi Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)
    Oscar Fernandez
    Fundacion IMABIS, Hospital Universitario Carlos Haya, Avda Carlos Haya s n, Malaga, Spain
    Rev Neurol 54:734-49. 2012
    ..This aspect reinforces the importance of disease registries as a proactive tool for monitoring drug safety in the post-approval setting...
  10. ncbi Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)
    Oscar Fernandez
    Hospital Regional Universitario Carlos Haya, Malaga, Espana
    Rev Neurol 54:677-91. 2012
    ..Systemic inflammation may contribute to neurodegeneration processes in MS, and with regard to grey matter damage recent findings conclude that occurs early in disease course, and correlates with future MS-related disability...
  11. doi Multiple sclerosis prevalence in Malaga, Southern Spain estimated by the capture-recapture method
    O Fernandez
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Spain
    Mult Scler 18:372-6. 2012
    ..The European Mediterranean countries are situated in a zone of median frequency, although ever increasing figures have been noted in the last decades...
  12. doi Oral laquinimod treatment in multiple sclerosis
    O Fernandez
    Instituto de Neurociencias clínicas, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    Neurologia 26:111-7. 2011
    ....
  13. doi Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires
    Oscar Fernandez
    Institute of Clinical Neurosciences, Hospital Regional University Carlos Haya, Spain
    Mult Scler 17:1238-49. 2011
    ..Multiple sclerosis (MS) can have psychological and socioeconomic consequences that affect patients' health-related quality of life (HRQoL) as much as physical disability...
  14. ncbi The effectiveness of glatiramer acetate in clinical practice: an observational study
    Oscar Fernández-Fernández
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Malaga, Espana
    Rev Neurol 54:1-9. 2012
    ..To evaluate the clinical effectiveness and safety of glatiramer acetate for use in routine clinical practice...
  15. ncbi [Review of the novelties presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)]
    O Fernandez-Fernandez
    Hospital Universitario Carlos Haya, 29190 Malaga, Espana
    Rev Neurol 52:289-99. 2011
    ..Regarding non pharmacologic therapies, behavioral intervention has emerged as an effective therapy in the treatment of depression in multiple sclerosis, showing additional benefits on fatigue, disability and adherence to treatment...
  16. ncbi [Review of the novelties presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)]
    Oscar Fernández-Fernández
    Fundacion IMABIS, Hospital Universitario Carlos Haya, Avda Carlos Haya s n, Malaga, Spain
    Rev Neurol 52:227-38. 2011
    ..The available data hold the potential therapeutic role of mesenchymal cells given the involvement of these stem cells in CNS repair...
  17. ncbi Azathioprine and methotrexate in multiple sclerosis
    O Fernandez
    Instituto de Neurociencias, Servicio de Neurologia, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    J Neurol Sci 223:29-34. 2004
    ..Methotrexate may alter the course of disease favourably in patients with progressive MS, but the evidence is again sparse...
  18. ncbi Interferons in relapsing-remitting multiple sclerosis: are there benefits from long-term use?
    Oscar Fernandez
    Institute of Neurosciences, Neurology Service, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    CNS Drugs 18:1057-70. 2004
    ..While there is no reason to suspect that IFNbeta should not continue to be efficacious and safe over the longer term, studies investigating these questions over longer periods and including greater numbers of patients are needed...
  19. ncbi HLA class II and response to interferon-beta in multiple sclerosis
    O Fernandez
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    Acta Neurol Scand 112:391-4. 2005
    ..To study the relationship between human leucocyte antigen (HLA) genotype and clinical response to interferon-beta (IFN-beta)...
  20. doi Multiple sclerosis in Gypsies from southern Spain: prevalence, mitochondrial DNA haplogroups and HLA class II association
    O Fernandez
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    Tissue Antigens 71:426-33. 2008
    ..DQB1*0602 was the strongest positive association found with Gypsy MS patients, and DRB1*1501-DQB1*0602 was the most frequent haplotype in this group...
  21. doi Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study)
    O Fernandez
    Hospital Regional Universitario Carlos Haya, Malaga, Spain
    J Neurol 257:1500-7. 2010
    ..Thus, it is during this initial period that greater effort is required in order to reduce the time to diagnosis, by increasing awareness of the problem of MS among the general population and primary care physicians...
  22. ncbi The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study
    Oscar Fernandez
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    Mult Scler 17:192-7. 2011
    ..Little is known about how the level of disability at the start of treatment with natalizumab affects its efficacy...
  23. ncbi Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)
    Oscar Fernandez
    Hospital Regional Universitario Carlos Haya, Malaga, Espana
    Rev Neurol 57:217-29. 2013
    ..Among the possible mechanisms involved in these processes of inflammation and demyelination, the role of Th17 cells, mitochondrial dysfunction, early disruption of astrocytic processes, and chronic hypoxia are discussed. ..
  24. ncbi Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III)
    Oscar Fernandez
    Fundacion IMABIS, Hospital Universitario Carlos Haya, 29190 Malaga, Espana
    Rev Neurol 57:317-29. 2013
    ....
  25. doi HLA class II alleles in patients with multiple sclerosis in the Biscay province (Basque Country, Spain)
    Oscar Fernandez
    Department of Neurology, Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Avda Carlos Haya s n, 29010 Malaga, Spain
    J Neurol 256:1977-88. 2009
    ..3.8% in MS, Pc = 0.00047, OR = 0.290 (95% CI = 0.160–0.528)], and suggesting, therefore, a putative protective role for this haplotype in the population under study...
  26. doi The CD4+ T-cell subset lacking expression of the CD28 costimulatory molecule is expanded and shows a higher activation state in multiple sclerosis
    María Jesús Pinto-Medel
    Research Laboratory, Hospital Regional Universitario Carlos Haya and Fundación IMABIS, Malaga, Spain
    J Neuroimmunol 243:1-11. 2012
    ..All these changes could provide these CD4(+)CD28(-) T-cell characteristics that might be involved in the pathogenesis of MS, turning this T-cell subset into a potential target for future therapeutic strategies...
  27. pmc Validation of the spanish version of the Multiple Sclerosis International Quality of Life (Musiqol) questionnaire
    Oscar Fernandez
    Institute of Clinical Neurosciences, Service of Neurology, Hospital Regional Universitario Carlos Haya, Avda, Carlos Haya s n, 29010 Malaga, Spain
    BMC Neurol 11:127. 2011
    ..We investigated the validity and reliability of the Spanish version of MusiQoL in Spain...
  28. ncbi Interferon receptor expression in multiple sclerosis patients
    Begoña Oliver
    Research Laboratory, Carlos Haya Hospital, Malaga, Spain
    J Neuroimmunol 183:225-31. 2007
    ..IFNbeta influences the expression of its receptors, and is greater in patients who respond to IFNbeta treatment. This down-regulation could be indicative of the response to IFNbeta...
  29. doi Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months
    Begoña Oliver
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    Mult Scler 17:368-71. 2011
    ..Although no antibodies were detected after 4 months of therapy in this particular study, this does not rule out their development later on in exceptional cases...
  30. ncbi Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study
    Oscar Fernandez
    Servicio de Neurologia, Complejo Hospitalario Carlos Haya Avda, Carlos Haya, 29010 Malaga, Spain
    J Neurol 249:1058-62. 2002
    ..In conclusion, combination therapy with IFNB-1b and AZA was safe and generally well tolerated in patients with SPMS. Strict clinical and laboratory monitoring is recommended during this combination therapy...
  31. pmc TRAIL/TRAIL receptor system and susceptibility to multiple sclerosis
    Carlos López-Gómez
    Research Laboratory, Clinical Neurosciences Institute, Hospital Regional Universitario Carlos Haya and Fundación IMABIS, Malaga, Spain
    PLoS ONE 6:e21766. 2011
    ..12×10(-5), OR = 0.59). These results suggest that genes of the TRAIL/TRAIL receptor system exerts a genetic influence on MS...
  32. pmc Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients
    Carlos López-Gómez
    Research Laboratory, Clinical Neurosciences Institute, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    PLoS ONE 8:e62540. 2013
    ..These findings show a role for TRAILR-1 gene variations in the clinical outcome of IFN beta therapy that might have relevance as a biomarker to predict the response to IFN beta in MS...
  33. ncbi Biomarkers in multiple sclerosis: an update for 2014
    Oscar Fernandez
    Fundacion IMABIS, Hospital Universitario Carlos Haya, 29190 Malaga, Espana
    Rev Neurol 58:553-70. 2014
    ..This review presents an update on the information available about the biomarkers that are currently validated and used in multiple sclerosis, together with the possible candidates for utilisation in routine clinical practice. ..
  34. ncbi Killer-cell immunoglobulin-like receptor expression on lymphocyte subsets in multiple sclerosis patients treated with interferon-β: evaluation as biomarkers for clinical response
    Juan A García-León
    UGC Neurociencias Clínicas, Instituto de Biomedicina de Málaga IBIMA, Hospital Regional Universitario de Málaga, Malaga, Spain
    CNS Drugs 28:559-70. 2014
    ..Both the adaptative and the innate immune systems interplay in multiple sclerosis (MS) pathogeny. Killer-cell immunoglobulin-like receptors (KIRs) are key regulators of the immune response, with activating and inhibitory isoforms...
  35. ncbi DQB1*0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain
    O Fernandez
    Dept of Neurology, Hospital Regional Universitario Carlos Haya, Avda Carlos Haya s n, 29010 Malaga, Spain
    J Neurol 251:440-4. 2004
    ..The human leukocyte antigen (HLA) class II DR2 haplotype (DRB1*1501, DQA1*0102, DQB1*0602) has been associated with multiple sclerosis (MS) in all ethnic groups and very strongly in Caucasians...
  36. ncbi [Usefulness of electronic drug registers: Spanish register of patients treated with fingolimod (Gilenya ®)]
    Oscar Fernandez
    Fundacion IMABIS, Hospital Universitario Carlos Haya, 29190 Malaga, Espana
    Rev Neurol 58:77-83. 2014
    ..The system is intended to serve as a tool to monitor its utilisation in daily clinical practice and thus allow optimisation of the way it is used...
  37. ncbi Combination therapy in multiple sclerosis
    Oscar Fernandez
    Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Malaga, Spain
    J Neurol Sci 259:95-103. 2007
    ..A wise balance between efficacy and safety and extremely clear information to patients should drive clinical decisions...
  38. ncbi Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients
    O Fernandez
    Neurology Service, Carlos Haya Hospital, Malaga, Spain
    J Neurol 248:383-8. 2001
    ..This may be due to the non-glycosylated, chemical structure of the former, which can produce aggregates and enhance antibody production. No association was found between the presence of NABs and the clinical status of the patients...
  39. ncbi Mechanisms and current treatments of urogenital dysfunction in multiple sclerosis
    Oscar Fernandez
    Neurological Service, Complejo Hospitalario Carlos Haya, Malaga, Spain
    J Neurol 249:1-8. 2002
    ..As most urogenital symptoms of MS can now be treated by conservative means, expert urological or gynaecological consultation should be requested only if more aggressive diagnostic or therapeutic measures are needed...